Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
DISCUSSION: Implications of on-going phase III trials are: 1) combination therapy of bevacizumab with atezolizumab may be the most anticipated studies for approvals ; 2) mirvetuximab soravtansine plus chemotherapy may generate positive results to justify an approval; and 3) Immune therapy for EOC may bring new treatments for the patients.
PMID: 30585545 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Guo Q, Yang Q, Li J, Liu G, Nikoulin I, Jia S Tags: Curr Pharm Biotechnol Source Type: research
More News: Avastin | Biology | Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Epithelial Cancer | Government | Molecular Biology | Ovarian Cancer | Ovaries | Study | USA Health